Rasburicase Induced Hemolysis in A Patient with
Undiagnosed Glucose 6 Phosphate Dehydrogenase
(G6PD) Deficiency

Lorie Ann Foster; Nancy Lin; Ki Hong Oh; Anna Andrzejczyk; Alison T Stopeck

Case Report

Rasburicase Induced Hemolysis in A Patient with Undiagnosed Glucose 6 Phosphate Dehydrogenase (G6PD) Deficiency

Lorie Ann Foster¹*, Nancy Lin¹, Ki Hong Oh², Anna Andrzejczyk³ and Alison T Stopeck³

¹Stony Brook Internal Medicine Residency Program, Stony Brook Medicine, USA

²Renaissance School of Medicine at Stony Brook University

²Division of Hematology and Oncology, Department of Medicine, Stony Brook Medicine

Corresponding Author

Received Date:January 17, 2024; Published Date:February 01, 2024

Abstract

Rasburicase is a recombinant urate oxidase effective in lowering uric acid accumulation in patients with hematologic and solid tumor malignancies receiving anti-cancer therapy [1]. Its use has also been associated with increased financial burden and morbidity when used inappropriately. When used in patients who are deficient in glucose-6-phosphate dehydrogenase (G6PD), it often results in life threatening acute hemolytic anemia. We report an interesting case of a 74-year-old female treated with rasburicase for presumed tumor lysis syndrome (TLS) who later developed acute hemolytic anemia secondary to G6PD deficiency. Here we highlight and emphasize how to minimize inappropriate use of rasburicase and how to recognize patients with increased risk for developing G6PD deficiency

Article Details

Citation

Lorie Ann Foster*, Nancy Lin, Ki Hong Oh, Anna Andrzejczyk and Alison T Stopeck. Rasburicase Induced Hemolysis in A Patient with Undiagnosed Glucose 6 Phosphate Dehydrogenase (G6PD) Deficiency. Arch Clin Case Stud. 3(5): 2024. ACCS. MS.ID.000571.